- All
- News
First Patient Enrolled in a Phase 2 Study in Patients with Type 2 Diabetes with Olatec’s NLRP3 Inhibitor, Dapansutrile
*Article in French* Read an article made by our partner “the Federation Française des diabétiques” about the project’s coordinator Nicolas Venteclef and the project INTERCEPT-T2D in their newsletter
The consortium met again in Basel on the 6&7 of December to review the progress and accomplishments of the year 2023.
Listen to Dr. Marc Donath, Head of Clinic for Endocrinology, Diabetes & Metabolism, Uni Spital Basel speaking about INTERCEPT-T2D
The coordinator and its lab were present at the annual meeting of the diabetic society..
The project kick-off has taken place on the 11th and 12th of January in Paris at Necker Institute.
